The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

A closer look at today's Trending Tickers - the stocks making the biggest moves worldwide - including Eli Lilly (LLY), Novo ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...